Clinical Role of FDG PET/CT for Methotrexate-Related Malignant Lymphoma

2011 ◽  
Vol 36 (7) ◽  
pp. 533-537 ◽  
Author(s):  
Ryogo Minamimoto ◽  
Kimiteru Ito ◽  
Kazuo Kubota ◽  
Miyako Morooka ◽  
Yoko Masuda-Miyata ◽  
...  
Keyword(s):  
Malignant Lymphoma ◽  
Fdg Pet ◽  
Clinical Role ◽  
Pet Ct ◽  
Fdg Pet Ct

Clinical role of early dynamic FDG-PET/CT for the evaluation of renal cell carcinoma

2015 ◽  
Vol 26 (6) ◽  
pp. 1852-1862 ◽  
Author(s):  
Reiko Nakajima ◽  
Koichiro Abe ◽  
Tsunenori Kondo ◽  
Kazunari Tanabe ◽  
Shuji Sakai
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Fdg Pet ◽  
Renal Cell ◽  
Clinical Role ◽  
Pet Ct ◽  
Fdg Pet Ct

scholarly journals The Clinical Role of Dual-Time-Point 18F-FDG PET/CT in Differential Diagnosis of the Thyroid Incidentaloma

2013 ◽  
Vol 48 (2) ◽  
pp. 121-129 ◽  
Author(s):  
Sinae Lee ◽  
Taegyu Park ◽  
Soyeon Park ◽  
Kisoo Pahk ◽  
Seunghong Rhee ◽  
...  
Keyword(s):  
Differential Diagnosis ◽  
Fdg Pet ◽  
Clinical Role ◽  
Thyroid Incidentaloma ◽  
Pet Ct ◽  
18F Fdg ◽  
Dual Time Point ◽  
Fdg Pet Ct ◽  
Time Point

W1061 The Clinical Role of 3-Dimensional F-18 FDG PET/CT Gastrography in Early and Advanced Gastric Cancer

2009 ◽  
Vol 136 (5) ◽  
pp. A-645
Author(s):  
Byung-Ik Jang ◽  
Tae Nyeun Kim ◽  
Jong Ryul Eun ◽  
Si Hyung Lee ◽  
Kyeong Ok Kim ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Fdg Pet ◽  
Clinical Role ◽  
3 Dimensional ◽  
Pet Ct ◽  
Ct Gastrography ◽  
Fdg Pet Ct

Hybrid Imaging in Evaluation of Abdominal Sarcoidosis

2018 ◽  
Vol 15 (1) ◽  
pp. 26-31 ◽  
Author(s):  
Isidora Grozdic Milojevic ◽  
Dragana Sobic-Saranovic ◽  
Nebojsa Petrovic ◽  
Slobodanka Beatovic ◽  
Marijana Tadic ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Therapy Response ◽  
Ct Examination ◽  
Abdominal Disease ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Total Remission ◽  
Active Disease

Objective: To determine the prevalence of abdominal involvement, distribution pattern and evaluate role of hybrid molecular imaging in patients with abdominal sarcoidosis. Methods: Between January 2010 and December 2011, 98 patients with chronic sarcoidosis and presence of prolonged symptoms or other findings suggestive of active disease were referred to FDG PET/CT examination. Active disease was found in 82 patients, and they all were screened for the presence of abdominal sarcoidosis on FDG PET/CT. All patients also underwent MDCT and assessment of serum ACE level. Follow up FDG PET/CT examination was done 12.3±5.4 months after the baseline. Results: Abdominal sarcoidosis was present in 31/82 patients with active sarcoidosis. FDG uptake was present in: retroperitoneal lymph nodes (77%), liver (26%), spleen (23%), adrenal gland (3%). Majority of patients had more than two locations of disease. Usually thoracic disease was spread into the extrathoracic localizations, while isolated abdominal sarcoidosis was present in 10% of patients. After first FDG PET/CT examination therapy was changed in all patients. Eleven patients came to the follow up examination where SUVmax significantly decreased in the majority of them. Three patients had total remission, three had absence of abdominal disease but discrete findings in thorax and others had less spread disease. ACE levels did not correlate with SUVmax level. Conclusion: FDG PET/CT can be a useful tool for detection of abdominal sarcoidosis and in the evaluation of therapy response in these patients. Awareness of the presence of intra-abdominal sarcoidosis is important in order to prevent long-standing unrecognized disease.

Sign in / Sign up

Export Citation Format

Share Document